Mika Nakao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mika Nakao has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Yukari Tsubata
Department of Respiratory Medicine Gifu University Graduate School of Medicine Gifu Japan
4 shared publications - Noriaki Kurimoto
Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine Shimane University Faculty of Medicine Izumo Japan
3 shared publications - Takamasa Hotta
Division of Medical Oncology and Respiratory Medicine, Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo, Japan
3 shared publications - Kazuhisa Nakashima
Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine Shimane University Faculty of Medicine Izumo Shimane Japan
2 shared publications - Megumi Hamaguchi
Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine Shimane University Faculty of Medicine Izumo Shimane Japan
2 shared publications - Misato Kobayashi
Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine Shimane University Faculty of Medicine Izumo Japan
2 shared publications
Latest Publications
- Open Access
- 28 November 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (23) , 3029
Bronchial Physiological Saline Injection to Visualize Peripheral Pulmonary Lesions in Ultrathin Bronchoscopy
Background: During bronchial lavage, the lumen can be viewed better by injecting physiological saline into the bronchus. This study aimed to investigate the effect of injecting physiological saline into the bronchus while directly observing the bronchial lumen with peripheral pulmonary lesions using an ultrathin bronchoscope. Methods: We evaluated changes in the depth of field and signal-to-noise ratio due to saline immersion in bronchoscopic images captured with line patterns. We injected physiological saline through the working channel into the bronchial lumen and directly observed the lesions (mainly in cases of suspected peripheral lung cancer) in 38 patients using white-light and narrow-band imaging. Ultrathin bronchoscopic findings and histopathological diagnoses were analyzed. Results: Saline immersion extended the range of subject distance within the depth of the field with an improved signal-to-noise ratio. Saline immersion elevated the signal-to-noise ratio and increased the highest signal-to-noise ratio in the white-light images from 3.12 dB to 3.77 dB (1.21-fold). Under narrow-band imaging, saline immersion also increased the highest signal-to-noise ratio from 5.18 dB to 6.44 dB (1.24-fold). We were able to directly observe the bronchial lumen of the peripheral lesions in 30/38 cases (78.9%). Three (60%) of the five squamous cell carcinomas were of the epithelial type, and 12 (92%) of the 13 adenocarcinomas, including peripheral pulmonary lesions, were of the subepithelial type, similar to central lesions. Conclusions: Injecting saline into the peripheral bronchus is useful for direct bronchoscopic evaluation of peripheral lesions.
- 28 November 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (23) , 3029
Open AccessBronchial Physiological Saline Injection to Visualize Peripheral Pulmonary Lesions in Ultrathin Bronchoscopy
Background: During bronchial lavage, the lumen can be viewed better by injecting physiological saline into the bronchus. This study aimed to investigate the effect of injecting physiological saline into the bronchus while directly observing the bronchial lumen with peripheral pulmonary lesions using an ultrathin bronchoscope. Methods: We evaluated changes in the depth of field and signal-to-noise ratio due to saline immersion in bronchoscopic images captured with line patterns. We injected physiological saline through the working channel into the bronchial lumen and directly observed the lesions (mainly in cases of suspected peripheral lung cancer) in 38 patients using white-light and narrow-band imaging. Ultrathin bronchoscopic findings and histopathological diagnoses were analyzed. Results: Saline immersion extended the range of subject distance within the depth of the field with an improved signal-to-noise ratio. Saline immersion elevated the signal-to-noise ratio and increased the highest signal-to-noise ratio in the white-light images from 3.12 dB to 3.77 dB (1.21-fold). Under narrow-band imaging, saline immersion also increased the highest signal-to-noise ratio from 5.18 dB to 6.44 dB (1.24-fold). We were able to directly observe the bronchial lumen of the peripheral lesions in 30/38 cases (78.9%). Three (60%) of the five squamous cell carcinomas were of the epithelial type, and 12 (92%) of the 13 adenocarcinomas, including peripheral pulmonary lesions, were of the subepithelial type, similar to central lesions. Conclusions: Injecting saline into the peripheral bronchus is useful for direct bronchoscopic evaluation of peripheral lesions.
- 2 December 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 197, 113469
A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)
- 2 December 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 197, 113469
A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)
- Open Access
- 1 May 2023
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 16, 2125-2132
A Retrospective Study of Pneumococcal Pneumonia in Hospitalized Patients Aged ≥65 Years in Izumo, Japan: 2010 to 2014
In Japan, both a 23-valent pneumococcal polysaccharide vaccine (PPSV23) and a 13-valent pneumococcal conjugate vaccine (PCV13) are available. Although randomized controlled trials have examined the effects of pneumococcal vaccines, few epidemiological studies have investigated the onset of pneumococcal pneumonia in general practice. In Izumo, Shimane Prefecture, Japan, a public subsidy for PPSV23 inoculation began in November 2012. The subjects were pneumonia patients aged 65 and over who were admitted to a hospital in Izumo. This retrospective study analyzed the following data extracted from medical records: pneumococcal pneumonia prevalence, pneumonia severity, mortality rate, PPSV23 vaccination rate, and length of hospital stay. The 2 years before the start of the public subsidy were defined as the early phase, and the 2 years after the subsidy initiation were defined as the late phase. We compared the two phases in terms of PPSV23 vaccination rate, prevalence and severity of pneumococcal pneumonia, and mortality rate. We investigated data from a total of 1188 and 1086 patients in the early and late phases, respectively. The prevalence of pneumococcal pneumonia was 21.0% and 21.3% in the early and late phases, respectively. The mortality rate from pneumococcal pneumonia was 10.4% and 5.4% in the early and late phases, respectively (p = 0.080), indicating a 50% reduction. The PPSV23 vaccination rate (p < 0.001) and the comorbidity rates of chronic respiratory disease (p = 0.022) and chronic renal disease (p < 0.001) were significantly different between the early and late phases. This study showed that the rate of in-hospital deaths due to pneumococcal pneumonia was halved after the PPSV23 vaccine was subsidized. The causal relationship between the pneumococcal vaccination rate and the mortality rate of pneumococcal disease was unclear. Further investigation is deemed necessary.
- 1 May 2023
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 16, 2125-2132
Open AccessA Retrospective Study of Pneumococcal Pneumonia in Hospitalized Patients Aged ≥65 Years in Izumo, Japan: 2010 to 2014
In Japan, both a 23-valent pneumococcal polysaccharide vaccine (PPSV23) and a 13-valent pneumococcal conjugate vaccine (PCV13) are available. Although randomized controlled trials have examined the effects of pneumococcal vaccines, few epidemiological studies have investigated the onset of pneumococcal pneumonia in general practice. In Izumo, Shimane Prefecture, Japan, a public subsidy for PPSV23 inoculation began in November 2012. The subjects were pneumonia patients aged 65 and over who were admitted to a hospital in Izumo. This retrospective study analyzed the following data extracted from medical records: pneumococcal pneumonia prevalence, pneumonia severity, mortality rate, PPSV23 vaccination rate, and length of hospital stay. The 2 years before the start of the public subsidy were defined as the early phase, and the 2 years after the subsidy initiation were defined as the late phase. We compared the two phases in terms of PPSV23 vaccination rate, prevalence and severity of pneumococcal pneumonia, and mortality rate. We investigated data from a total of 1188 and 1086 patients in the early and late phases, respectively. The prevalence of pneumococcal pneumonia was 21.0% and 21.3% in the early and late phases, respectively. The mortality rate from pneumococcal pneumonia was 10.4% and 5.4% in the early and late phases, respectively (p = 0.080), indicating a 50% reduction. The PPSV23 vaccination rate (p < 0.001) and the comorbidity rates of chronic respiratory disease (p = 0.022) and chronic renal disease (p < 0.001) were significantly different between the early and late phases. This study showed that the rate of in-hospital deaths due to pneumococcal pneumonia was halved after the PPSV23 vaccine was subsidized. The causal relationship between the pneumococcal vaccination rate and the mortality rate of pneumococcal disease was unclear. Further investigation is deemed necessary.
- Open Access
- 6 March 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (5) , 1003
Comparison of Ultra-Magnifying Endocytoscopic and Hematoxylin-Eosin-Stained Images of Lung Specimens
Endocytoscopy enables real-time observation of lesions at ultra-magnification. In the gastrointestinal and respiratory fields, endocytoscopic images are similar to hematoxylin-eosin-stained images. This study aimed to compare the nuclear features of pulmonary lesions in endocytoscopic and hematoxylin-eosin-stained images. We performed an endocytoscopy to observe resected specimens of normal lung tissue and lesions. Nuclear features were extracted using ImageJ. We analyzed five nuclear features: nuclear number per area, mean nucleus area, median circularity, coefficient of variation of roundness, and median Voronoi area. We conducted dimensionality reduction analyses for these features, followed by assessments of the inter-observer agreement among two pathologists and two pulmonologists to evaluate endocytoscopic videos. We analyzed the nuclear features of hematoxylin-eosin-stained and endocytoscopic images from 40 and 33 cases, respectively. Endocytoscopic and hematoxylin-eosin-stained images displayed a similar tendency for each feature, despite there being no correlation. Conversely, the dimensionality reduction analyses demonstrated similar distributions of normal lung and malignant clusters in both images, thus differentiating between the clusters. The diagnostic accuracy of the pathologists was 58.3% and 52.8% (κ-value 0.38, fair), and that of the pulmonologists was 50% and 47.2% (κ-value 0.33, fair). The five nuclear features of pulmonary lesions were similar in the endocytoscopic and hematoxylin-eosin-stained images.
- 6 March 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (5) , 1003
Open AccessComparison of Ultra-Magnifying Endocytoscopic and Hematoxylin-Eosin-Stained Images of Lung Specimens
Endocytoscopy enables real-time observation of lesions at ultra-magnification. In the gastrointestinal and respiratory fields, endocytoscopic images are similar to hematoxylin-eosin-stained images. This study aimed to compare the nuclear features of pulmonary lesions in endocytoscopic and hematoxylin-eosin-stained images. We performed an endocytoscopy to observe resected specimens of normal lung tissue and lesions. Nuclear features were extracted using ImageJ. We analyzed five nuclear features: nuclear number per area, mean nucleus area, median circularity, coefficient of variation of roundness, and median Voronoi area. We conducted dimensionality reduction analyses for these features, followed by assessments of the inter-observer agreement among two pathologists and two pulmonologists to evaluate endocytoscopic videos. We analyzed the nuclear features of hematoxylin-eosin-stained and endocytoscopic images from 40 and 33 cases, respectively. Endocytoscopic and hematoxylin-eosin-stained images displayed a similar tendency for each feature, despite there being no correlation. Conversely, the dimensionality reduction analyses demonstrated similar distributions of normal lung and malignant clusters in both images, thus differentiating between the clusters. The diagnostic accuracy of the pathologists was 58.3% and 52.8% (κ-value 0.38, fair), and that of the pulmonologists was 50% and 47.2% (κ-value 0.33, fair). The five nuclear features of pulmonary lesions were similar in the endocytoscopic and hematoxylin-eosin-stained images.
- Open Access
- 1 March 2022
- Published by Elsevier in Respiratory Investigation
- Vol. 60 (2) , 215-220
Results of 10-year mobile low-dose computed tomography screenings for lung cancer in Shimane, Japan
- 1 March 2022
- Published by Elsevier in Respiratory Investigation
- Vol. 60 (2) , 215-220
Open AccessResults of 10-year mobile low-dose computed tomography screenings for lung cancer in Shimane, Japan
- Open Access
- 1 October 2019
- Published by Elsevier in Annals of Oncology
- Vol. 30 (Supplement) , v604
Clinical development of molecular-targeted therapies for non-small cell lung cancer through nationwide genome screening in Japan (LC-SCRUM-Japan)
A nationwide genome screening project in Japan (LC-SCRUM-Japan) has been established for the development of molecular-targeted therapies for lung cancers. Since 2013, ALK/ROS1/RET fusions have been analyzed by RT-PCR and FISH, and since 2015, multi-gene alterations have been also analyzed by a next-generation sequencing (NGS) system, Oncomine™ Comprehensive Assay. A large-scale clinico-genomic database has been developed based on the molecular screening and the monitoring of therapeutic efficacy and patient survival. As of December, 2018, 263 institutions were participating and 5360 non-squamous non-small cell lung cancer patients had been enrolled. The success rates of RT-PCR and NGS were 94% and 91%, respectively. Of 4874 available samples, a total of 2135 targetable gene alterations (521 KRAS mut, 157 ROS1 fus, 136 MET ex14skip/amp, 131 BRAF mut, 128 ERBB2 ex20ins, 126 RET fus, 118 ALK fus, 73 EGFR ex20ins, 10 AKT1 mut, 9 NRG1 fus, 6 FGFR2/3 fus, 2 NTRK3 fus and others) were detected. Through this screening, 963 genotype-matched patients to molecular-targeted clinical trials were identified, and 172 of them (18%) were enrolled into the trials, resulting in the approval of ROS1- and BRAF-targeted therapies in Japan. Based on our database, in patients with EGFR/ERBB2 ex20ins, MET ex14skip and RET fusions, the median overall survivals were 18.5 (95%CI, 15.4-28.1), 38.0 (8.8-NR) and 51.3 (33.4-73.4) months, respectively. In these 3 subtypes, the objective response rate of 1st-line platinum-containing chemotherapies were 33%, 23% and 30%, respectively, and the progression-free survivals were 6.0 (95%CI, 5.0-7.0), 6.8 (4.4-8.4) and 10.5 (8.1-15.2) months, respectively. These historical data are valuable for evaluating efficacy of novel targeted drugs. Our large-scale screening and clinico-genomic database contribute to the development of novel targeted therapies, especially for ROS1-, BRAF-, EGFR/ERBB2 ex20ins-, MET- and RET-positive lung cancers. In addition to the tissue-based NGS assay, NGS with liquid biopsy and multi-target qPCR assay will be started for further development of targeted drugs and companion diagnostics from 2019 in LC-SCRUM-Japan. UMIN000010234. National Cancer Center Japan. Astellas Pharma, AstraZeneca, Amgen, Eisai, Ono Pharmaceutical, Kyowa Hakko Kirin, MSD, Merck Serono, Daiichi Sankyo, Taiho Pharmaceutical, Takeda Pharmaceutical, Pfizer, Novartis Pharma, Eily Lilly. S. Matsumoto: Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): Chugai Pharma; Honoraria (self): Pfizer; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): MSD. K. Yoh: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Lilly Japan; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Chugai Pharma; Honoraria (self): Boehringer Ingelheim; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self), Research grant / Funding (institution): Daiichi Sankyo; Honoraria (self): Kirin Pharmaceuticals ; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Taiho Pharmaceutical; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Ono Pharmaceutical. T. Kato: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Lilly; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Chugai Pharma; Advisory / Consultancy: Nitto Denko; Advisory / Consultancy, Research grant / Funding (institution): AbbVie; Advisory / Consultancy: Merck Serono; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Honoraria (self): Roche; Honoraria (self): Boehringer Ingelheim; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical ; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self): Bristol-Myers Squibb Japan; Honoraria (self), Research grant / Funding (institution): Merck Sharp & Dohme; Honoraria (self): Novartis; Honoraria (self): Sumitomo Dainippon Pharma; Honoraria (self): Quintiles; Honoraria (self): Takeda; Research grant / Funding (institution): Kyowa Hakko Kirin; Research grant / Funding (institution): Astellas Pharma . K. Nishino: Honoraria (self): Chugai Pharma. S. Sugawara: Honoraria (self): AstraZeneca; Honoraria (self): Chugai Pharma ; Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): Taiho Pharmaceutical ; Honoraria (self): Pfizer ; Honoraria (self): Lilly; Honoraria (self): Novartis; Honoraria (self): Kyowa Hakko Kirin; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Ono Pharmaceutical; Honoraria (self): MSD K.K . Y. Ohe: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Chugai Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Lilly Japan; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Kyorin ; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Takeda; Honoraria (self), Advisory / Consultancy: Celltrion; Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb Japan; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Bayer; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): MSD ; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self): Kyowa Hakko Kirin; Research grant / Funding (institution): Sumitomo Dainippon Pharma; Research grant / Funding (institution): Ignyta. T. Seto: Honoraria (self): Astellas Pharma; Honoraria (self), Research grant / Funding (institution): AstraZeneca ; Honoraria (self): Bristol-Myers Squibb; Honoraria (self), Research grant / Funding (institution): Chugai Pharma; Honoraria (self), Research grant / Funding (institution): Lilly; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self), Research grant / Funding (institution): Nippon Boehringer Ingelheim; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Takeda; Honoraria (self): Thermo Fisher Scientific; Research grant / Funding (institution): Bayer Yakuhin; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Kissei Pharmaceutical; Research grant / Funding (institution): Loxo; Research grant / Funding (institution): Merck Serono. N. Furuya: Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self): Bristol-Myers Squibb Japan; Honoraria (self): Lilly; Honoraria (self): Chugai Pharma; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Ono Pharmaceutical . K. Goto: Advisory / Consultancy: Otsuka; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Chugai Pharma; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical ; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): Lilly; Honoraria (self), Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (self): Quintiles; Honoraria (self), Research grant / Funding (institution): Merck Serono; Honoraria (self), Research grant / Funding (institution): Life Technologies; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self): AbbVie; Honoraria (self), Research grant / Funding (institution): Riken Genesis; Honoraria (self): Nippon Kayaku; Honoraria (self), Research grant / Funding (institution): Takeda; Honoraria (self): Otsuka; Honoraria (self): SRL Diagnostics. All other authors have declared no conflicts of interest.
- 1 October 2019
- Published by Elsevier in Annals of Oncology
- Vol. 30 (Supplement) , v604
Open AccessClinical development of molecular-targeted therapies for non-small cell lung cancer through nationwide genome screening in Japan (LC-SCRUM-Japan)
A nationwide genome screening project in Japan (LC-SCRUM-Japan) has been established for the development of molecular-targeted therapies for lung cancers. Since 2013, ALK/ROS1/RET fusions have been analyzed by RT-PCR and FISH, and since 2015, multi-gene alterations have been also analyzed by a next-generation sequencing (NGS) system, Oncomine™ Comprehensive Assay. A large-scale clinico-genomic database has been developed based on the molecular screening and the monitoring of therapeutic efficacy and patient survival. As of December, 2018, 263 institutions were participating and 5360 non-squamous non-small cell lung cancer patients had been enrolled. The success rates of RT-PCR and NGS were 94% and 91%, respectively. Of 4874 available samples, a total of 2135 targetable gene alterations (521 KRAS mut, 157 ROS1 fus, 136 MET ex14skip/amp, 131 BRAF mut, 128 ERBB2 ex20ins, 126 RET fus, 118 ALK fus, 73 EGFR ex20ins, 10 AKT1 mut, 9 NRG1 fus, 6 FGFR2/3 fus, 2 NTRK3 fus and others) were detected. Through this screening, 963 genotype-matched patients to molecular-targeted clinical trials were identified, and 172 of them (18%) were enrolled into the trials, resulting in the approval of ROS1- and BRAF-targeted therapies in Japan. Based on our database, in patients with EGFR/ERBB2 ex20ins, MET ex14skip and RET fusions, the median overall survivals were 18.5 (95%CI, 15.4-28.1), 38.0 (8.8-NR) and 51.3 (33.4-73.4) months, respectively. In these 3 subtypes, the objective response rate of 1st-line platinum-containing chemotherapies were 33%, 23% and 30%, respectively, and the progression-free survivals were 6.0 (95%CI, 5.0-7.0), 6.8 (4.4-8.4) and 10.5 (8.1-15.2) months, respectively. These historical data are valuable for evaluating efficacy of novel targeted drugs. Our large-scale screening and clinico-genomic database contribute to the development of novel targeted therapies, especially for ROS1-, BRAF-, EGFR/ERBB2 ex20ins-, MET- and RET-positive lung cancers. In addition to the tissue-based NGS assay, NGS with liquid biopsy and multi-target qPCR assay will be started for further development of targeted drugs and companion diagnostics from 2019 in LC-SCRUM-Japan. UMIN000010234. National Cancer Center Japan. Astellas Pharma, AstraZeneca, Amgen, Eisai, Ono Pharmaceutical, Kyowa Hakko Kirin, MSD, Merck Serono, Daiichi Sankyo, Taiho Pharmaceutical, Takeda Pharmaceutical, Pfizer, Novartis Pharma, Eily Lilly. S. Matsumoto: Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): Chugai Pharma; Honoraria (self): Pfizer; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): MSD. K. Yoh: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Lilly Japan; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Chugai Pharma; Honoraria (self): Boehringer Ingelheim; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self), Research grant / Funding (institution): Daiichi Sankyo; Honoraria (self): Kirin Pharmaceuticals ; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Taiho Pharmaceutical; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Ono Pharmaceutical. T. Kato: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Lilly; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Chugai Pharma; Advisory / Consultancy: Nitto Denko; Advisory / Consultancy, Research grant / Funding (institution): AbbVie; Advisory / Consultancy: Merck Serono; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Honoraria (self): Roche; Honoraria (self): Boehringer Ingelheim; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical ; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self): Bristol-Myers Squibb Japan; Honoraria (self), Research grant / Funding (institution): Merck Sharp & Dohme; Honoraria (self): Novartis; Honoraria (self): Sumitomo Dainippon Pharma; Honoraria (self): Quintiles; Honoraria (self): Takeda; Research grant / Funding (institution): Kyowa Hakko Kirin; Research grant / Funding (institution): Astellas Pharma . K. Nishino: Honoraria (self): Chugai Pharma. S. Sugawara: Honoraria (self): AstraZeneca; Honoraria (self): Chugai Pharma ; Honoraria (self): Nippon Boehringer Ingelheim; Honoraria (self): Taiho Pharmaceutical ; Honoraria (self): Pfizer ; Honoraria (self): Lilly; Honoraria (self): Novartis; Honoraria (self): Kyowa Hakko Kirin; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Ono Pharmaceutical; Honoraria (self): MSD K.K . Y. Ohe: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Chugai Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Lilly Japan; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Kyorin ; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Takeda; Honoraria (self), Advisory / Consultancy: Celltrion; Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb Japan; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Bayer; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): MSD ; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self): Kyowa Hakko Kirin; Research grant / Funding (institution): Sumitomo Dainippon Pharma; Research grant / Funding (institution): Ignyta. T. Seto: Honoraria (self): Astellas Pharma; Honoraria (self), Research grant / Funding (institution): AstraZeneca ; Honoraria (self): Bristol-Myers Squibb; Honoraria (self), Research grant / Funding (institution): Chugai Pharma; Honoraria (self), Research grant / Funding (institution): Lilly; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self), Research grant / Funding (institution): Nippon Boehringer Ingelheim; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Takeda; Honoraria (self): Thermo Fisher Scientific; Research grant / Funding (institution): Bayer Yakuhin; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Kissei Pharmaceutical; Research grant / Funding (institution): Loxo; Research grant / Funding (institution): Merck Serono. N. Furuya: Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self): Bristol-Myers Squibb Japan; Honoraria (self): Lilly; Honoraria (self): Chugai Pharma; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Ono Pharmaceutical . K. Goto: Advisory / Consultancy: Otsuka; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Chugai Pharma; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical ; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): Lilly; Honoraria (self), Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (self): Quintiles; Honoraria (self), Research grant / Funding (institution): Merck Serono; Honoraria (self), Research grant / Funding (institution): Life Technologies; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self): AbbVie; Honoraria (self), Research grant / Funding (institution): Riken Genesis; Honoraria (self): Nippon Kayaku; Honoraria (self), Research grant / Funding (institution): Takeda; Honoraria (self): Otsuka; Honoraria (self): SRL Diagnostics. All other authors have declared no conflicts of interest.